MED Company Profile and Key Details

The latest quarter delivered EPS of -$0.65. The next quarter is forecast at -$0.52. Next year's EPS is expected at -$43.21. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $15.00. The high target offers 18.76% upside. The low target suggests 18.76% downside. The mean target is $15.00. This offers 18.76% upside. Medifast, Inc. earnings surprise history is a mixed track record. The quarter that ended August 03, 2026, missed forecasts by 0.0%. The prior quarter beat by -65.45%. Over the last six quarters, Apple has recorded several small beats. These include 57.14% in April 28, 2025.

MED has shown mixed momentum, losing -0.26% over the past week and -9.75% over the past quarter, though year-to-date performance is up 9.18%. Short-term trend indicators are bullishly aligned (SMA20 -4.41%, SMA50 -7.02%, SMA200 -17.93%). The stock’s 14-day RSI is 37.36 (weak momentum), while the ATR of 0.44 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -32.54% below its high and over 3.27% above its low. Average 10-day trading volume of 126.38 thousand shares is below the 3-month average of 206.82 thousand, indicating normal recent market interest.

Medifast, Inc. last paid a dividend of 0 per share, this equals a trailing yield of roughly 17.57%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $501.46. This means the shares are trading below this model’s fair value.

Medifast, Inc. has 11.18 million shares outstanding. The public float is 8.38 million shares, elevated short interest at 13.75% of float. This equals 1.48 million shares. The short ratio is 8.84 days. Institutional investors hold 89.09% of the float. Insiders own 4.19%. SCHLACKMAN SCOTT holds 30.55 thousand shares, Kiai Parsa has 20.27 thousand shares and Chard Daniel R has 17.68 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Medifast, Inc. (NYSE:MED) closed at $12.18 USD, losing -$0.46 (-3.60%) from the previous close of $12.63. The stock is currently mid-range between its 52-week high and low $9.22 and $14.67. With a market capitalization of about $135.38 million, Medifast, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.73). Key stats such as the average daily volume over the past year has been around 208.38 thousand shares, volume is running light vs its 52-week average. Headquartered in Baltimore, MD, Medifast, Inc. operates in the Consumer Cyclical sector and the Personal Products & Services industry. Led by CEO Nicholas Johnson, the company employs approximately 380 people and listed since December 30, 1993. Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness.

Medifast, Inc. trades at a P/E ratio of -5.42, slightly below the S&P 500 average, with a price-to-sales ratio of 0.44 and a price-to-book ratio of 0.72 suggesting the stock is closer to book value. The P/FCF stands at 34.99, also above market averages.

Our AI price prediction model suggests that Medifast, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.89%, with price expected at $13.50 by September 18, 2026, within a range of $12.67 to $14.44 3-Month Outlook: Projected rise of 16.39%, reaching $14.70 by December 03, 2026, with a range of $13.94 to $15.31. 1-Year Outlook: Projected gain of 30.09%, with price at $16.43 by September 03, 2027, within a range of $7.39 to $16.90.

Medifast, Inc. (NYSE:MED) shares are flat 9.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Medifast, Inc. trading at a premium to the broader market with a P/E of -5.42. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $79.54, suggesting 529.77% upside. Our AI forecast model points to short-term strength (6.89% over two weeks), a medium-term rise (16.39% over three months), and a longer-term gain (30.09% over one year), with expected trading ranges indicating moderate volatility.